复发难治型弥漫大 B 细胞淋巴瘤的新疗法

昊禄 孙(内蒙古医科大学，中国)
阿荣 金(内蒙古自治区人民医院，中国)

摘要

成人非霍奇金淋巴瘤中最常见的类型是弥漫大B细胞淋巴瘤（Diffuse Large B-cell Lymphoma，DLBCL）。虽然大多数患 者对一线治疗R-CHOP方案都有反应，但仍有30%~40%的DLBCL患者反复发作或不能通过一线治疗得到缓解，进展为复 发/难治型弥漫大B细胞淋巴瘤（Relapsed/Refractory Diffuse Large B-cell Lymphoma，R/R DLBCL），可行自体干细胞移植 （Autologous Stem Cell Transplantation，ASCT）或嵌合抗原受体T细胞疗法（Chimeric Antigen Receptor T-cell，CAR-T） 进行治疗。但仍存在某些R/R DLBCL患者不符合ASCT或CAR-T的条件，或在ASCT或CAR-T治疗后复发或疗效不佳。 近些年来，一些新型药物已经获得批准，如Tafasitamab联合来那度胺、维泊珠单抗（Polatuzumab Vedotin）、塞利尼索 （Selinexor）、Loncastuximab Tesirine和CAR-T细胞产品：Glofitamab，这为难以治疗的人群提供了新的机会。论文回顾了 R/R DLBCL目前批准的新型疗法。

关键词

弥漫大B细胞淋巴瘤；复发/难治型；新疗法；治疗不良反应

参考

SHINGLETON J, WANG J, BALOH C, et al. Non-Hodgkin

Lymphomas: Malignancies Arising from Mature B Cells [J]. Cold

Spring Harbor perspectives in medicine,2021,11(3).

SEHN L H, SALLES G. Diffuse Large B-Cell Lymphoma [J]. The

New England journal of medicine,2021,384(9):842-858.

FERRY J A. Scientific Advances and the Evolution of Diagnosis,

Subclassification and Treatment of Lymphoma [J]. Archives of

medical research,2020,51(8):749-764.

WANG L, LI L R, YOUNG K H. New agents and regimens for

diffuse large B cell lymphoma [J]. Journal of hematology &

oncology, 2020,13(1):175.

HE M Y, KRIDEL R. Treatment resistance in diffuse large B-cell

lymphoma [J]. Leukemia, 2021,35(8):2151-65.

POE J C, MINARD-COLIN V, KOUNTIKOV E I, et al. A c-Myc

and surface CD19 signaling amplification loop promotes B cell

lymphoma development and progression in mice [J]. Journal of

immunology (Baltimore, Md: 1950),2012,189(5):2318-2325.

DUELL J, MADDOCKS K J, GONZáLEZ-BARCA E, et al. Longterm outcomes from the Phase II L-MIND study of tafasitamab

(MOR208) plus lenalidomide in patients with relapsed or

refractory diffuse large B-cell lymphoma [J]. Haematologica,

,106(9):2417-2426.

DüLL J, TOPP M, SALLES G. The use of tafasitamab in diffuse

large B-cell lymphoma [J]. Therapeutic advances in hematolo

gy,2021,12:20406207211027458.

GRIBBEN J G, FOWLER N, MORSCHHAUSER F. Mechanisms

of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma

[J]. Journal of clinical oncology: official journal of the American

Society of Clinical Oncology,2015,33(25):2803-2811.

SALLES G, DUELL J, GONZáLEZ BARCA E, et al. Tafasitamab

plus lenalidomide in relapsed or refractory diffuse large B-cell

lymphoma (L-MIND): a multicentre, prospective, single-arm,

phase 2 study [J]. The Lancet Oncology,2020,21(7):978-88.

BELADA D, KOPECKOVA K, BERGUA BURGUES J M, et al.

Safety and efficacy of tafasitamab with or without lenalidomide

added to first-line R-CHOP for DLBCL: the phase 1b First-MIND

study [J]. Blood, 2023,142(16):1348-1358.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i5.17768